Ivan Sergeevich Ivanov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ivan Sergeevich Ivanov has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Denis Olegovich Shatalov
MIREA - Russian Technological University
14 shared publications - Diana Aleksandrovna Akhmedova
Russian Technological University
7 shared publications - Sergei V. Beliakov
Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
7 shared publications - Stanislav A. Kedik
MIREA – Russian Technological University (M.V. Lomonosov Institute of Fine Chemical Technologies)
7 shared publications - Anna Viktorovna Aydakova
Institutе of Рhаrmасеutiсаl Тесhnоlоgiеs
4 shared publications - Daria Kirillova
Department of Biotechnology and Industrial Pharmacy, Institute of Fine Chemical Technologies named after M.V. Lomonosov, MIREA - Russian Technological University , Moscow, Russian Federation
4 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by The Korean Society of Environmental Health and Toxicology in Environmental Analysis Health and Toxicology
- Vol. 41 (4) , e2026023
Preclinical Toxicology of a Succinic Acid Salt of a Polyhexamethylene Guanidine Derivative: Acute and Repeated-Dose Studies
The growing interest in ocular antiseptics is driven by their broad-spectrum antimicrobial activity and potential to mitigate antimicrobial resistance. In a previous study, systemic effects of ophthalmic drops based on succinic acid derivative of polyhexamethylene guanidine (ss-PHMGd) following ocular instillation were investigated in a preclinical model. The present study aimed to assess the acute toxicity of ss-PHMGd in mice and outbred rats of both sexes after intragastric and ocular administration, its cumulative properties in rats using the Lim method, and its toxicity under repeated dosing conditions, including intraperitoneal administration in rats for 7 days and topical ocular application in Chinchilla rabbits for 30 days. Acute toxicity evaluation showed LD50 values of 672.3 mg/kg in male mice and 693.4 mg/kg in female mice following intragastric administration. No mortality was observed after ocular administration in mice and rats, precluding the determination of toxic or lethal dose levels for this route. The cumulation coefficient (K = 1.76) indicated no cumulative properties. Repeated-dose studies revealed no significant effects on general condition or behavior in rats and rabbits at the tested doses. However, histopathological examination identified pathological changes in the lungs and thyroid gland in some rats after intraperitoneal administration at a dose equivalent to 10 therapeutical doses (TD) (0.3 mg/kg). These findings contribute to the understanding of polyguanidines and are relevant for toxicological evaluation and risk assessment of ss-PHMGd.
- 12 November 2026
- Published by The Korean Society of Environmental Health and Toxicology in Environmental Analysis Health and Toxicology
- Vol. 41 (4) , e2026023
Open AccessPreclinical Toxicology of a Succinic Acid Salt of a Polyhexamethylene Guanidine Derivative: Acute and Repeated-Dose Studies
The growing interest in ocular antiseptics is driven by their broad-spectrum antimicrobial activity and potential to mitigate antimicrobial resistance. In a previous study, systemic effects of ophthalmic drops based on succinic acid derivative of polyhexamethylene guanidine (ss-PHMGd) following ocular instillation were investigated in a preclinical model. The present study aimed to assess the acute toxicity of ss-PHMGd in mice and outbred rats of both sexes after intragastric and ocular administration, its cumulative properties in rats using the Lim method, and its toxicity under repeated dosing conditions, including intraperitoneal administration in rats for 7 days and topical ocular application in Chinchilla rabbits for 30 days. Acute toxicity evaluation showed LD50 values of 672.3 mg/kg in male mice and 693.4 mg/kg in female mice following intragastric administration. No mortality was observed after ocular administration in mice and rats, precluding the determination of toxic or lethal dose levels for this route. The cumulation coefficient (K = 1.76) indicated no cumulative properties. Repeated-dose studies revealed no significant effects on general condition or behavior in rats and rabbits at the tested doses. However, histopathological examination identified pathological changes in the lungs and thyroid gland in some rats after intraperitoneal administration at a dose equivalent to 10 therapeutical doses (TD) (0.3 mg/kg). These findings contribute to the understanding of polyguanidines and are relevant for toxicological evaluation and risk assessment of ss-PHMGd.
- Open Access
- 5 December 2025
- Published by The Korean Society of Environmental Health and Toxicology in Environmental Analysis Health and Toxicology
- Vol. 40 (4) , e2025027
Preclinical pharmacokinetics and tissue distribution of a polyhexamethylene guanidine derivative after ocular mucosal administration
Antibiotic resistance is a critical medical issue. Antiseptics, which play a key role in treating and preventing eye infections and inflammations, have the potential to induce resistance in pathogenic microorganisms despite their broad antimicrobial spectrum. When introducing new active substances into ophthalmic treatments, it is crucial to assess the risk of side effects caused by the systemic action of the active compound. The succinic salt of polyhexamethylene guanidine derivative (ss-PHMGd) has shown high in vitro activity. This study aimed to evaluate the systemic effects of ss-PHMGd-based eye drops after ocular instillation in a preclinical model. Simple mathematical models were used to calculate pharmacokinetic parameters during instillation in two types of laboratory animals: guinea pigs and chinchilla rabbits. Groups received intravenous injections and ocular treatments. Tritium-labeled ss-PHMGd was used to quantify its concentration in organs and tissues. To test the linearity of the parameter relationships, data from three different doses were compared. Renal excretion was studied by quantifying ss-PHMGd concentrations in urine using radiometric methods. The results showed that ss-PHMGd-based eye drops present a low risk of systemic side effects and exhibit minimal penetration into other organs after instillation. No species-specific differences were found in the ADME parameters of the preclinical models (the guinea pig-to-chinchilla rabbit absorption ratio was 0.7). The AUC-D parameters exhibited a linear relationship for doses ranging from 0.5 of therapeutic dose (TD) to 5TD in guinea pigs. Renal excretion analysis revealed that 5.3% of the administered dose was excreted through the kidneys, indicating significant metabolic transformation or excretion via other pathways. This study enhances the understanding of the pharmacokinetics and safety of polyguanidines, with implications for toxicology and risk assessment.
- 5 December 2025
- Published by The Korean Society of Environmental Health and Toxicology in Environmental Analysis Health and Toxicology
- Vol. 40 (4) , e2025027
Open AccessPreclinical pharmacokinetics and tissue distribution of a polyhexamethylene guanidine derivative after ocular mucosal administration
Antibiotic resistance is a critical medical issue. Antiseptics, which play a key role in treating and preventing eye infections and inflammations, have the potential to induce resistance in pathogenic microorganisms despite their broad antimicrobial spectrum. When introducing new active substances into ophthalmic treatments, it is crucial to assess the risk of side effects caused by the systemic action of the active compound. The succinic salt of polyhexamethylene guanidine derivative (ss-PHMGd) has shown high in vitro activity. This study aimed to evaluate the systemic effects of ss-PHMGd-based eye drops after ocular instillation in a preclinical model. Simple mathematical models were used to calculate pharmacokinetic parameters during instillation in two types of laboratory animals: guinea pigs and chinchilla rabbits. Groups received intravenous injections and ocular treatments. Tritium-labeled ss-PHMGd was used to quantify its concentration in organs and tissues. To test the linearity of the parameter relationships, data from three different doses were compared. Renal excretion was studied by quantifying ss-PHMGd concentrations in urine using radiometric methods. The results showed that ss-PHMGd-based eye drops present a low risk of systemic side effects and exhibit minimal penetration into other organs after instillation. No species-specific differences were found in the ADME parameters of the preclinical models (the guinea pig-to-chinchilla rabbit absorption ratio was 0.7). The AUC-D parameters exhibited a linear relationship for doses ranging from 0.5 of therapeutic dose (TD) to 5TD in guinea pigs. Renal excretion analysis revealed that 5.3% of the administered dose was excreted through the kidneys, indicating significant metabolic transformation or excretion via other pathways. This study enhances the understanding of the pharmacokinetics and safety of polyguanidines, with implications for toxicology and risk assessment.
- Open Access
- 29 October 2024
- Published by Etflin in Sciences of Pharmacy
- Vol. 3 (4) , 220-229
Development of Chitosan-Based Antimicrobial Hydrogel Incorporating Polyvinylpyrrolidone and PHMG
This study focuses on the development of a chitosan-based hydrogel incorporating polyvinylpyrrolidone and polyhexamethylene guanidine hydrochloride for the rehabilitation of damaged and contaminated skin. The thermal properties of chitosan-containing films were characterized by measuring the glass transition temperature (Tg) using differential scanning calorimetry. Due to challenges in accurately determining the Tg of chitosan from experimental and literature data, an additional method, dynamic mechanical analysis, was employed. Using the literature value for the Tg of polyhexamethylene guanidine hydrochloride, the transitions of the components were determined. The estimated sorption capacity of the developed hydrogel showed that the inclusion of polyhexamethylene guanidine hydrochloride reduced the moisture content, as expected. However, the overall behavior of the hydrogels remained similar. Vapor permeability, an important factor in wound healing, was also evaluated. Antimicrobial testing revealed no activity for the chitosan control sample despite some reports in the literature, while the samples containing polyhexamethylene guanidine hydrochloride exhibited superior antimicrobial efficacy. These findings suggest that the incorporation of polyhexamethylene guanidine hydrochloride and polyvinylpyrrolidone significantly enhances both the mechanical strength and antimicrobial potential of chitosan-based hydrogels, positioning them as promising candidates for the treatment of contaminated wounds.
- 29 October 2024
- Published by Etflin in Sciences of Pharmacy
- Vol. 3 (4) , 220-229
Open AccessDevelopment of Chitosan-Based Antimicrobial Hydrogel Incorporating Polyvinylpyrrolidone and PHMG
This study focuses on the development of a chitosan-based hydrogel incorporating polyvinylpyrrolidone and polyhexamethylene guanidine hydrochloride for the rehabilitation of damaged and contaminated skin. The thermal properties of chitosan-containing films were characterized by measuring the glass transition temperature (Tg) using differential scanning calorimetry. Due to challenges in accurately determining the Tg of chitosan from experimental and literature data, an additional method, dynamic mechanical analysis, was employed. Using the literature value for the Tg of polyhexamethylene guanidine hydrochloride, the transitions of the components were determined. The estimated sorption capacity of the developed hydrogel showed that the inclusion of polyhexamethylene guanidine hydrochloride reduced the moisture content, as expected. However, the overall behavior of the hydrogels remained similar. Vapor permeability, an important factor in wound healing, was also evaluated. Antimicrobial testing revealed no activity for the chitosan control sample despite some reports in the literature, while the samples containing polyhexamethylene guanidine hydrochloride exhibited superior antimicrobial efficacy. These findings suggest that the incorporation of polyhexamethylene guanidine hydrochloride and polyvinylpyrrolidone significantly enhances both the mechanical strength and antimicrobial potential of chitosan-based hydrogels, positioning them as promising candidates for the treatment of contaminated wounds.
- Open Access
- 2 August 2024
- Published by Etflin in Sciences of Pharmacy
- Vol. 3 (3) , 153-166
Toxicity and Safety Analysis of Polyhexamethylene Guanidine: A Comprehensive Systematic Review
Polyhexamethylene guanidine (PHMG) is a commonly used disinfectant, but safety concerns have arisen due to poisoning cases. This systematic review assesses the toxicity and safety of PHMG by inhalation, oral administration, skin contact, and ocular contact to determine its potential medical applications and acceptable concentration limits. Searches in PubMed, ScienceDirect, CENTRAL, and CyberLeninka up to January 2024 identified 11 in vitro studies with human cell lines, 28 animal studies, and 10 articles involving patients and healthy volunteers. The review found that inhalation of PHMG leads to pulmonary fibrosis and malignant neoplasms, making aerosol forms unacceptable. PHMG can also affect liver function and have adverse effects on the heart, kidneys, and hematopoietic system. For dermal use, PHMG appears to be safe at concentrations up to 3%, although practical use may limit this to 1% due to potential discomfort. Still, it is important to consider possible sensitization, especially in patients with pre-existing skin conditions. In oral hygiene, 1% PHMG-P has been used safely in periodontal treatment, suggesting its potential in dentistry. For ophthalmic use, concentrations should be carefully monitored. PHMG-P solutions below 0.13% appear to be safe for human corneal epithelium, however lower concentrations still pose a risk of corneal fibrosis, as shown in animal studies. Physicians should prefer lower concentrations and consider alternatives or formulations with reduced toxicity for sensitive applications such as eye drops. Overall, although PHMG and its derivatives show promise in a variety of medical applications, their use should be reasonable, with careful consideration of the associated risks.
- 2 August 2024
- Published by Etflin in Sciences of Pharmacy
- Vol. 3 (3) , 153-166
Open AccessToxicity and Safety Analysis of Polyhexamethylene Guanidine: A Comprehensive Systematic Review
Polyhexamethylene guanidine (PHMG) is a commonly used disinfectant, but safety concerns have arisen due to poisoning cases. This systematic review assesses the toxicity and safety of PHMG by inhalation, oral administration, skin contact, and ocular contact to determine its potential medical applications and acceptable concentration limits. Searches in PubMed, ScienceDirect, CENTRAL, and CyberLeninka up to January 2024 identified 11 in vitro studies with human cell lines, 28 animal studies, and 10 articles involving patients and healthy volunteers. The review found that inhalation of PHMG leads to pulmonary fibrosis and malignant neoplasms, making aerosol forms unacceptable. PHMG can also affect liver function and have adverse effects on the heart, kidneys, and hematopoietic system. For dermal use, PHMG appears to be safe at concentrations up to 3%, although practical use may limit this to 1% due to potential discomfort. Still, it is important to consider possible sensitization, especially in patients with pre-existing skin conditions. In oral hygiene, 1% PHMG-P has been used safely in periodontal treatment, suggesting its potential in dentistry. For ophthalmic use, concentrations should be carefully monitored. PHMG-P solutions below 0.13% appear to be safe for human corneal epithelium, however lower concentrations still pose a risk of corneal fibrosis, as shown in animal studies. Physicians should prefer lower concentrations and consider alternatives or formulations with reduced toxicity for sensitive applications such as eye drops. Overall, although PHMG and its derivatives show promise in a variety of medical applications, their use should be reasonable, with careful consideration of the associated risks.
- 2 April 2024
- Published by ECO-Vector LLC in Bulletin of the Russian Military Medical Academy
- Vol. 26 (1) , 35-50
Application of a mixed type of optimization in the implementation of pharmaceutical development of a dosage form of eye drops based on oligohexamethyleneguanidine hydrosuccinate
This study focused on the implementation of the stages of pharmaceutical development of a dosage form of eye drops based on the branched oligohexamethylene guanidine hydrosuccinate according to discrete and continuous optimization, followed by risk assessment and process validation. Experimental samples were developed, critical process and quality parameters were identified, technological characteristics were measured, parameters were normalized, a forecast was made, confirmatory experiments were conducted, the optimal composition was identified, risks in the production of eye drops were assessed, and partial validation was performed. During the implementation of the stages of pharmaceutical development of eye drops based on branched oligohexamethylene guanidine hydrosuccinate, three optimization cycles (discrete and continuous) were carried out, and the optimal ratio of active and auxiliary components was justified based on the results (branched oligohexamethylene guanidine hydrosuccinate 0.05%, polyvinyl alcohol 1%, phosphate-buffered saline 20%, sodium chloride 0.45%, and purified water up to 100%). After reviewing the technological process considering risk analysis, critical points were identified, and partial validation was performed, and the positive results verified and confirmed the optimal choice at this stage of pharmaceutical development. In general, a mixed type of optimization (discrete and continuous) can be used to implement pharmaceutical developments of eye drops based on branched oligohexamethylene guanidine hydrosuccinate, which is confirmed by a series of experiments and risk assessment, and the partial validation verified the data obtained. Thus, pharmaceutical development is a complex and time-consuming process, and limited functionality does not always allow quick identification of the optimal composition of a drug. As an effective solution for implementing the stages of pharmaceutical development, mathematical modeling methods and various types of optimization can be applied.
- 2 April 2024
- Published by ECO-Vector LLC in Bulletin of the Russian Military Medical Academy
- Vol. 26 (1) , 35-50
Application of a mixed type of optimization in the implementation of pharmaceutical development of a dosage form of eye drops based on oligohexamethyleneguanidine hydrosuccinate
This study focused on the implementation of the stages of pharmaceutical development of a dosage form of eye drops based on the branched oligohexamethylene guanidine hydrosuccinate according to discrete and continuous optimization, followed by risk assessment and process validation. Experimental samples were developed, critical process and quality parameters were identified, technological characteristics were measured, parameters were normalized, a forecast was made, confirmatory experiments were conducted, the optimal composition was identified, risks in the production of eye drops were assessed, and partial validation was performed. During the implementation of the stages of pharmaceutical development of eye drops based on branched oligohexamethylene guanidine hydrosuccinate, three optimization cycles (discrete and continuous) were carried out, and the optimal ratio of active and auxiliary components was justified based on the results (branched oligohexamethylene guanidine hydrosuccinate 0.05%, polyvinyl alcohol 1%, phosphate-buffered saline 20%, sodium chloride 0.45%, and purified water up to 100%). After reviewing the technological process considering risk analysis, critical points were identified, and partial validation was performed, and the positive results verified and confirmed the optimal choice at this stage of pharmaceutical development. In general, a mixed type of optimization (discrete and continuous) can be used to implement pharmaceutical developments of eye drops based on branched oligohexamethylene guanidine hydrosuccinate, which is confirmed by a series of experiments and risk assessment, and the partial validation verified the data obtained. Thus, pharmaceutical development is a complex and time-consuming process, and limited functionality does not always allow quick identification of the optimal composition of a drug. As an effective solution for implementing the stages of pharmaceutical development, mathematical modeling methods and various types of optimization can be applied.
- Open Access
- 22 December 2023
- Published by Etflin in Sciences of Pharmacy
- Vol. 3 (1) , 39-49
Sterility of Ophthalmic Solutions as a Factor in the Evolution of Primary Packaging for Eye Drops: A Literature Review
Preservatives in eye drops, while not always necessary, can lead to undesirable effects. Developing preservative-free solutions demands special measures for sterility, utilizing multidose or monodose primary packaging. This review explores the merits and drawbacks of these packaging types. A literature search on PubMed, Google Scholar, and EMBASE until December 2023, using MESH terms, yielded 28 studies on multidose ampoules and 24 on monodose packaging. Heterogeneous data revealed advantages and disadvantages concerning patient use and manufacturing. Chronologically presenting the development of eye drop packaging, this study finds Droptainer® simple but unable to maintain sterility. Comod®, 3K®, ABAK®, Novelia®, and Ophthalmic Squeeze Dispenser show high sterility probability, with Comod® and ABAK® having a contamination risk. Novelia® excels with long-term sterility and better control. Ophthalmic Squeeze Dispenser, FDA-approved, boasts a smaller carbon footprint. Unit-dose systems preserve sterility and offer design flexibility. Proposing an alternative, blister technology maintains sterility, is convenient and safe, and holds promise for recycling. This comprehensive assessment aids in understanding the evolving landscape of eye drop packaging, emphasizing the importance of sterility, convenience, and environmental impact.
- 22 December 2023
- Published by Etflin in Sciences of Pharmacy
- Vol. 3 (1) , 39-49
Open AccessSterility of Ophthalmic Solutions as a Factor in the Evolution of Primary Packaging for Eye Drops: A Literature Review
Preservatives in eye drops, while not always necessary, can lead to undesirable effects. Developing preservative-free solutions demands special measures for sterility, utilizing multidose or monodose primary packaging. This review explores the merits and drawbacks of these packaging types. A literature search on PubMed, Google Scholar, and EMBASE until December 2023, using MESH terms, yielded 28 studies on multidose ampoules and 24 on monodose packaging. Heterogeneous data revealed advantages and disadvantages concerning patient use and manufacturing. Chronologically presenting the development of eye drop packaging, this study finds Droptainer® simple but unable to maintain sterility. Comod®, 3K®, ABAK®, Novelia®, and Ophthalmic Squeeze Dispenser show high sterility probability, with Comod® and ABAK® having a contamination risk. Novelia® excels with long-term sterility and better control. Ophthalmic Squeeze Dispenser, FDA-approved, boasts a smaller carbon footprint. Unit-dose systems preserve sterility and offer design flexibility. Proposing an alternative, blister technology maintains sterility, is convenient and safe, and holds promise for recycling. This comprehensive assessment aids in understanding the evolving landscape of eye drop packaging, emphasizing the importance of sterility, convenience, and environmental impact.
- 26 September 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-5
Gas Stations Performance Modeling in Terms of Geoanalytics
A conceptual approach has been developed to solve the location problem, allowing commercial organizations that own gas stations to assess the degree of influence of geographical characteristics of locations on profitability indicators. Data collection, processing, and spatial analysis have been conducted to build a model for forecasting financial results.
- 26 September 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-5
Gas Stations Performance Modeling in Terms of Geoanalytics
A conceptual approach has been developed to solve the location problem, allowing commercial organizations that own gas stations to assess the degree of influence of geographical characteristics of locations on profitability indicators. Data collection, processing, and spatial analysis have been conducted to build a model for forecasting financial results.
- Open Access
- 2 August 2023
- Published by RTU MIREA in Fine Chemical Technologies
- Vol. 18 (3) , 265-279
Implementation of pharmaceutical development using multivariate analysis of multi-criteria optimization on the example of the stage of purification of oligohexamethyleneguanidine hydrosuccinate
Objectives. The study set out to use mathematical modeling, in particular the method of multifactorial analysis of multicriteria optimization (MAMO), in the development of a pharmaceutical product.Methods. After carrying out experimental tests based on the proposed algorithmic sequence, the obtained data were interpreted using MAMO.Results. The possibility of using MAMO to solve the applied problem of purifying oligohexamethyleneguanidine hydrosuccinate (OHMG-HS), considered as a pharmaceutical precursor for the creation of medicines, was demonstrated.Conclusions. The expediency of using the proposed algorithm as a tool for pharmaceutical development is substantiated by identifying dependencies of the influence of purification conditions on the final content of admixtures in the target product.
- 2 August 2023
- Published by RTU MIREA in Fine Chemical Technologies
- Vol. 18 (3) , 265-279
Open AccessImplementation of pharmaceutical development using multivariate analysis of multi-criteria optimization on the example of the stage of purification of oligohexamethyleneguanidine hydrosuccinate
Objectives. The study set out to use mathematical modeling, in particular the method of multifactorial analysis of multicriteria optimization (MAMO), in the development of a pharmaceutical product.Methods. After carrying out experimental tests based on the proposed algorithmic sequence, the obtained data were interpreted using MAMO.Results. The possibility of using MAMO to solve the applied problem of purifying oligohexamethyleneguanidine hydrosuccinate (OHMG-HS), considered as a pharmaceutical precursor for the creation of medicines, was demonstrated.Conclusions. The expediency of using the proposed algorithm as a tool for pharmaceutical development is substantiated by identifying dependencies of the influence of purification conditions on the final content of admixtures in the target product.
- Open Access
- 7 September 2022
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 1-7
APPROACHES TO THE SEARCH OF THE OPTIMUM PACKAGING OF EYE DROPS
The purpose of this study is to find a unique ophthalmic packaging that takes into account modern requirements for both maintaining the quality and safety of the drug, compliance with therapy, and increasing the profitability and environmental friendliness of its production. Statistics from open international databases on drugs approved for ophthalmic therapy in 2022 are provided. The research criteria were a valid registration status, the type of packaging and the presence of a preservative in the composition of the eye drops. The results of statistical processing of databases of ministries of health of different countries have shown the relevance of monodose ophthalmic packaging, capable of long-term storage of the drug without preservatives. In many countries, particularly in Europe, many drugs in the form of a monodose containers are registered. On this basis, a unique aluminum-based monodose container design is proposed, eliminating the use of large quantities of plastic.
- 7 September 2022
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 1-7
Open AccessAPPROACHES TO THE SEARCH OF THE OPTIMUM PACKAGING OF EYE DROPS
The purpose of this study is to find a unique ophthalmic packaging that takes into account modern requirements for both maintaining the quality and safety of the drug, compliance with therapy, and increasing the profitability and environmental friendliness of its production. Statistics from open international databases on drugs approved for ophthalmic therapy in 2022 are provided. The research criteria were a valid registration status, the type of packaging and the presence of a preservative in the composition of the eye drops. The results of statistical processing of databases of ministries of health of different countries have shown the relevance of monodose ophthalmic packaging, capable of long-term storage of the drug without preservatives. In many countries, particularly in Europe, many drugs in the form of a monodose containers are registered. On this basis, a unique aluminum-based monodose container design is proposed, eliminating the use of large quantities of plastic.
- 2 November 2021
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 47 (11) , 1764-1774
Pharmacokinetic investigation of branched oligohexamethyleneguanidine hydrochloride in a liquid composition for the treatment of stomatitis and gingivitis
Branched oligohexamethyleneguanidine hydrochloride (branched OHMG-HC) possesses high biocidal activity. This study aimed at evaluating the pharmacokinetics of branched OHMG-HC and is mandatory for obtaining permission to conduct clinical studies. The thermal activation method was used to obtain radioactive-labeled drugs for the investigation of substance distribution in various tissues of experimental animals (rats and rabbits). Substance administration was carried out both orally (a dose was split into two equal volumes that were applied to buccal zones of the oral cavities of the animals) and intravenously to get a clear pharmacokinetic profile. In this research, the drug was applied in the concentration of 0.77 mg/kg with the addition of 0.037 mg/kg 3H-OHMG for rats, and 0.42 mg/kg with the addition of 0.015 mg/kg 3H-OHMG for Chinchilla rabbits. The selected samples of blood, organs and urine underwent alkaline mineralization. A quantitative determination of 3H-OHMG was carried out using a liquid β-, γ-counter according to the level of scintillation in the sample. Branched OHMG-HC displayed uniform distribution within all main organs and tissues upon oral administration. The highest concentrations were found in liver and kidney tissues, whereas the lowest in blood, cardiac muscle tissue and brain. The closeness of the fabs values obtained from different animals (24.5% for rats and 29.0% for rabbits) demonstrated the absence of the species specificity in response to the pharmaceutical substance. The main parameters of excretion were established, and the half-life time was estimated to be 15 hours.
- 2 November 2021
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 47 (11) , 1764-1774
Pharmacokinetic investigation of branched oligohexamethyleneguanidine hydrochloride in a liquid composition for the treatment of stomatitis and gingivitis
Branched oligohexamethyleneguanidine hydrochloride (branched OHMG-HC) possesses high biocidal activity. This study aimed at evaluating the pharmacokinetics of branched OHMG-HC and is mandatory for obtaining permission to conduct clinical studies. The thermal activation method was used to obtain radioactive-labeled drugs for the investigation of substance distribution in various tissues of experimental animals (rats and rabbits). Substance administration was carried out both orally (a dose was split into two equal volumes that were applied to buccal zones of the oral cavities of the animals) and intravenously to get a clear pharmacokinetic profile. In this research, the drug was applied in the concentration of 0.77 mg/kg with the addition of 0.037 mg/kg 3H-OHMG for rats, and 0.42 mg/kg with the addition of 0.015 mg/kg 3H-OHMG for Chinchilla rabbits. The selected samples of blood, organs and urine underwent alkaline mineralization. A quantitative determination of 3H-OHMG was carried out using a liquid β-, γ-counter according to the level of scintillation in the sample. Branched OHMG-HC displayed uniform distribution within all main organs and tissues upon oral administration. The highest concentrations were found in liver and kidney tissues, whereas the lowest in blood, cardiac muscle tissue and brain. The closeness of the fabs values obtained from different animals (24.5% for rats and 29.0% for rabbits) demonstrated the absence of the species specificity in response to the pharmaceutical substance. The main parameters of excretion were established, and the half-life time was estimated to be 15 hours.